Biologics

FDA Crackdown on CAR-T Promotion in Coordinated Action

David McFarland

— 1 min read
Share

CBER has issued four untitled letters in a single coordinated enforcement action, targeting promotional materials for leading T-cell therapies and signaling heightened scrutiny of how cutting-edge biologics are marketed. The letters fit into a wider FDA enforcement trend. Since late 2025, the agency has significantly increased scrutiny of promotional communications, particularly those that may exaggerate benefits or omit safety information. The new letters cite promotional violations for:

  • Kymriah (Novartis)
  • Tecartus (Kite Pharma)
  • Breyanzi (Bristol Myers Squibb / Juno Therapeutics)
  • Amtagvi (Iovance Biotherapeutics)

All four products are advanced therapies — primarily CAR-T or cell-based immunotherapies used in oncology — where clinical evidence is often evolving and approvals may rely on surrogate endpoints.

Across multiple letters, FDA objected to claims or implications that the therapies improve overall survival, progression-free survival, or relapse-free survival. In the Tecartus letter, for example, FDA said materials cited exploratory analyses and suggested clinical benefit not established in labeling, rendering the promotion “false or misleading” and causing the product to be misbranded.

Another common theme was the misuse of exploratory or secondary endpoints. FDA explicitly noted that such data — while scientifically relevant — “should be carefully interpreted” and cannot be promoted as definitive evidence of benefit.

Several of the products cited have indications granted under accelerated approval. FDA’s concern: promotional materials often omit or downplay this uncertainty, creating an inflated perception of efficacy. And FDA cited some firms for creating a misleading “net impression.” Even when individual statements are technically accurate, FDA repeatedly emphasizes the concept of net impression:

  • selective framing
  • omission of qualifiers
  • visual or contextual emphasis

Taken together, the letters constitute a coordinated enforcement action focused on a single therapeutic class — CAR-T and other cell therapies — signaling that FDA expects a higher level of rigor and discipline in their promotion.

Read more